Johnson & Johnson reported Phase 3 data showing Tecvayli improved outcomes versus widely used regimens in earlier settings of multiple myeloma. In the MajesTEC‑9 study, J&J said patients randomized to Tecvayli experienced a substantial reduction in the combined risk of death or disease progression compared with standard therapies, supporting the company’s push to move the drug into earlier lines of care. J&J detailed progression‑free survival as the primary endpoint and flagged survival benefits in secondary analyses; the company plans regulatory discussions and scientific presentations. For readers: Tecvayli is a bispecific antibody targeting key myeloma antigens and the company is positioning it as a backbone agent across earlier treatment lines, which could reshape payor and prescribing dynamics if regulators accept the data.